Valerio Therapeutics Société anonyme (EPA: ALVIO)
France
· Delayed Price · Currency is EUR 0.0760
0.00 (0.00%)
Dec 20, 2024, 4:34 PM CET
EPA: ALVIO Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Operating Revenue | 1.89 | 1.8 | 1.44 | 4.06 | 1.78 | 4.29 | Upgrade
|
| Other Revenue | - | - | - | - | - | 0 | Upgrade
|
| Revenue | 1.89 | 1.8 | 1.44 | 4.06 | 1.78 | 4.29 | Upgrade
|
| Revenue Growth (YoY) | 30.91% | 24.74% | -64.48% | 128.72% | -58.59% | -30.00% | Upgrade
|
| Cost of Revenue | 0.48 | 0.53 | 0.51 | 0.37 | 0.35 | 0.35 | Upgrade
|
| Gross Profit | 1.41 | 1.27 | 0.93 | 3.69 | 1.43 | 3.94 | Upgrade
|
| Selling, General & Admin | 17.4 | 19.57 | 18.02 | 8.12 | 8.15 | 12.67 | Upgrade
|
| Other Operating Expenses | -0.07 | 0.27 | 0.03 | 0.69 | 0.48 | 0.4 | Upgrade
|
| Operating Expenses | 19.38 | 20.32 | 18.04 | 9.28 | 9.24 | 13.73 | Upgrade
|
| Operating Income | -17.97 | -19.05 | -17.11 | -5.58 | -7.81 | -9.79 | Upgrade
|
| Interest Expense | -0.1 | -0.14 | -2.19 | -0.85 | -0.96 | -1.04 | Upgrade
|
| Interest & Investment Income | 0.14 | 0.17 | 0.14 | 0.01 | 0 | 0.02 | Upgrade
|
| Earnings From Equity Investments | - | - | - | - | - | -0.04 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.49 | -0.07 | -0.5 | 0.15 | 0.61 | -0.66 | Upgrade
|
| EBT Excluding Unusual Items | -18.41 | -19.09 | -19.67 | -6.28 | -8.16 | -11.51 | Upgrade
|
| Impairment of Goodwill | - | - | - | - | - | -2 | Upgrade
|
| Asset Writedown | - | - | - | - | - | -12.9 | Upgrade
|
| Other Unusual Items | -1.23 | -1.23 | 0.39 | 0.44 | 10.01 | -9.64 | Upgrade
|
| Pretax Income | -19.64 | -20.33 | -19.28 | -5.84 | 1.85 | -36.05 | Upgrade
|
| Income Tax Expense | 0.02 | 0.02 | 0.29 | 0.1 | 0.76 | -2.32 | Upgrade
|
| Net Income | -19.66 | -20.34 | -19.56 | -5.94 | 1.09 | -33.73 | Upgrade
|
| Net Income to Common | -19.66 | -20.34 | -19.56 | -5.94 | 1.09 | -33.73 | Upgrade
|
| Shares Outstanding (Basic) | 159 | 135 | 106 | 88 | 73 | 61 | Upgrade
|
| Shares Outstanding (Diluted) | 159 | 135 | 106 | 88 | 75 | 61 | Upgrade
|
| Shares Change (YoY) | 40.39% | 27.86% | 19.88% | 17.03% | 23.61% | 14.48% | Upgrade
|
| EPS (Basic) | -0.12 | -0.15 | -0.18 | -0.07 | 0.01 | -0.55 | Upgrade
|
| EPS (Diluted) | -0.12 | -0.15 | -0.18 | -0.07 | 0.01 | -0.55 | Upgrade
|
| Free Cash Flow | -16.44 | -18.78 | -9.93 | -8.71 | -4.8 | -7.73 | Upgrade
|
| Free Cash Flow Per Share | -0.10 | -0.14 | -0.09 | -0.10 | -0.06 | -0.13 | Upgrade
|
| Gross Margin | 74.75% | 70.39% | 64.38% | 90.94% | 80.46% | 91.84% | Upgrade
|
| Operating Margin | -951.03% | -1058.50% | -1185.93% | -137.42% | -439.98% | -228.35% | Upgrade
|
| Profit Margin | -1040.66% | -1130.22% | -1355.65% | -146.16% | 61.32% | -786.38% | Upgrade
|
| Free Cash Flow Margin | -870.09% | -1043.33% | -688.22% | -214.45% | -270.10% | -180.11% | Upgrade
|
| EBITDA | -16.46 | -18.92 | -17.04 | -5.54 | -7.69 | -9.56 | Upgrade
|
| EBITDA Margin | - | - | - | -136.26% | - | -222.97% | Upgrade
|
| D&A For EBITDA | 1.51 | 0.14 | 0.08 | 0.05 | 0.12 | 0.23 | Upgrade
|
| EBIT | -17.97 | -19.05 | -17.11 | -5.58 | -7.81 | -9.79 | Upgrade
|
| EBIT Margin | - | - | - | -137.42% | - | -228.35% | Upgrade
|
| Effective Tax Rate | - | - | - | - | 41.01% | - | Upgrade
|
| Revenue as Reported | 0.09 | - | - | - | 1.78 | 4.29 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.